Sponsor or institution

Clinical trials and research at Suzhou Alphamab Co., Ltd.

As of November 12, 2026, Find a Trial lists 4 clinical trials run by Suzhou Alphamab Co., Ltd. that are recruiting, in China. By phase: Phase 1 (2), Phase 1/2 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.

Newest trials

StudyPhaseWhereStatusRegistered
Long-term preventive KN057 treatment for Hemophilia A and B Phase 3 Tianjin, Tianjin Municipality Recruiting Apr 22, 2026
KN060 to prevent clotting during hemodialysis for people with end-stage kidney disease Phase 1/2 Beijing, Beijing Municipality Recruiting Oct 1, 2025
KN060 for adults with essential hypertension Phase 1 Shanghai, Shanghai Municipality Recruiting Sep 25, 2025
Evaluating KN069 for treating obesity in men Phase 1 Changsha, Hunan Recruiting Aug 9, 2024

All recruiting trials (4)

Quick answers

How many clinical trials run by Suzhou Alphamab Co., Ltd. are recruiting right now?

4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 2, Phase 1/2: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →

Last reviewed 2026-11-12 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.